Last reviewed · How we verify
GW685698/GW642444
GW685698/GW642444 is a long-acting beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to produce bronchodilation.
GW685698/GW642444 is a long-acting beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to produce bronchodilation. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | GW685698/GW642444 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
The drug binds to and activates beta-2 adrenergic receptors located on the smooth muscle of airways, leading to increased intracellular cAMP levels and smooth muscle relaxation. This results in sustained bronchodilation and improved airflow in patients with obstructive airway diseases. The long-acting formulation allows for once or twice-daily dosing.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
Key clinical trials
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (PHASE3)
- Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma (PHASE3)
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma (PHASE3)
- A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma (PHASE3)
- A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD (PHASE3)
- A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects (PHASE1)
- Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects (PHASE1)
- Corrected QT (QTc) Study With Flucticasone Furoate and GW642444 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW685698/GW642444 CI brief — competitive landscape report
- GW685698/GW642444 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI